Recent news highlights include regulatory approvals, Nasdaq compliance actions, dividend record date changes, and corporate publications related to Scilex Holding Co's products.

• Scilex Holding Company announced deferral of preferred stock dividend record date in June 2025 [N5].
• The company reported publication on GLOPERBA dosing adjustments in a peer-reviewed journal in June 2025 [N6].
• Scilex regained compliance with Nasdaq minimum closing bid price requirement as of April 30, 2025 [N7].
• Scilex won Health Canada approval for ELYXYB to treat acute migraine with or without aura in April 2025 [N7].
• The company announced a 1-for-35 reverse stock split to regain Nasdaq compliance in April 2025 [N7].
• Scilex announced new record dates for preferred stock dividends in April 2025 [N8].
• The FDA granted Scilex orphan drug status for colchicine to treat pericarditis and for Gloperba for the treatment of pericarditis in April 2025 [N8].

Scilex has multiple FDA-approved products with differentiated delivery technologies addressing large pain management markets with unmet needs. Its clinical candidates have advanced through pivotal trials and received Fast Track designations, indicating regulatory engagement. The company’s commercial infrastructure and managed care capabilities support product uptake and formulary inclusion. The cryptocurrency treasury strategy could provide alternative revenue streams and asset appreciation. Successful commercialization of pipeline products and expansion of the portfolio through acquisitions or in-licensing could enhance market presence and revenue diversification.

Scilex faces significant financial challenges, including a net loss of $45.65 million in Q1 2026 and a low liquidity position with a current ratio of 0.08, indicating potential short-term financial stress. The company’s reliance on a limited number of commercial products and ongoing clinical development programs exposes it to regulatory and clinical trial risks. The cryptocurrency treasury strategy introduces volatility and regulatory uncertainty. Market competition, potential termination rights by licensors, and the need for continued capital raise or financing pose execution risks. Failure to achieve commercial adoption or regulatory approvals for pipeline candidates could adversely impact business prospects.

Scilex's moat derives from its portfolio of FDA-approved non-opioid pain management products addressing significant unmet medical needs, supported by proprietary delivery technologies and exclusive licensing agreements. Its clinical-stage candidates have received FDA Fast Track designations, potentially expediting development. The company’s established commercial infrastructure, including a specialized sales force and managed care expertise, facilitates market penetration and formulary access. Its novel viscous gel formulation for epidural injections and unique topical systems provide differentiation. The cryptocurrency treasury strategy introduces a non-traditional asset management approach, though it carries regulatory and market risks.

• Financial Liquidity Risk: As of March 31, 2026, Scilex Holding Co had a current ratio of 0.08 and a cash ratio of 0.01, indicating limited short-term liquidity relative to current liabilities, which may constrain operational flexibility and require additional financing.
• Regulatory and Clinical Development Risk: The company’s product candidates, including SP-102, SP-103, and SP-104, are subject to regulatory approval processes and clinical trial outcomes that may delay or prevent commercialization.
• Cryptocurrency Treasury Strategy Risk: The adoption of a cryptocurrency treasury strategy exposes the company to market volatility, regulatory changes, and custody risks associated with digital assets.
• Market Competition and Commercial Execution Risk: Scilex operates in competitive pain management markets and depends on successful commercialization, market acceptance, and formulary coverage of its products to generate revenue.

• Scilex Holding Co is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment [S1].
• The company targets indications with high unmet needs and large market opportunities using non-opioid therapies [S1].
• Commercial products include: ZTlido (lidocaine topical system) 1.8%, FDA-approved for neuropathic pain associated with postherpetic neuralgia; ELYXYB, FDA-approved oral solution for acute migraine treatment; and GLOPERBA, FDA-approved liquid oral colchicine for gout prophylaxis, launched June 2024 [S1].
• Product candidates include SP-102 (SEMDEXA), a viscous gel corticosteroid for epidural injections to treat sciatica with completed Phase 3 study; SP-103, a triple-strength lidocaine topical system for acute pain with completed Phase 2 trial; and SP-104, a low-dose delayed-release naltrexone for fibromyalgia with completed Phase 1 trials [S1].
• The company has a commercial sales force of over 30 people targeting over 3,500 healthcare providers including primary care physicians, pain specialists, neurologists, and palliative care physicians [S1].
• ZTlido has achieved over 5.6% market share of the lidocaine patch prescription market in covered U.S. territories as of December 31, 2025 [S1].
• The company uses a multi-channel marketing strategy including direct-to-patient marketing and managed healthcare account executives to secure formulary coverage with major payors and pharmacy benefit managers [S1].
• Scilex has adopted a cryptocurrency treasury strategy focusing on long-term holdings of bitcoin, Ethereum, BNB, Doge, and other blockchain-linked cryptocurrencies, with plans to use professional treasury strategies including staking and yield-generating activities [S1].
• The company plans to establish a cryptocurrency advisory board and engage a third-party asset manager for day-to-day management of cryptocurrency holdings, which will be held in cold storage with third-party custodians [S1].
• Financial snapshot as of 2026-03-31 shows cash and equivalents of $3.35 million, current assets of $41.97 million, current liabilities of $501.75 million, resulting in a current ratio of 0.08 and cash ratio of 0.01 [S2].
• Revenue for the quarter ending 2026-03-31 was $8.61 million, with a net loss of $45.65 million and basic and diluted EPS of -$6.28 per share [S2].
• The company has completed a pivotal Phase 3 study for SP-102 and initiated a second Phase 3 study in September 2025 [S1].
• SP-103 received FDA Fast Track status for acute low back pain and showed safety and tolerability in Phase 2 trials [S1].
• The company has secured Health Canada approval for ELYXYB to treat acute migraine with or without aura [N7].
• Scilex announced a 1-for-35 reverse stock split to regain Nasdaq compliance [N7].
• The company has announced deferral and changes of record dates for preferred stock dividends [N5, N8].
• Scilex received FDA orphan drug designation for colchicine to treat pericarditis and for Gloperba for the treatment of pericarditis [N8].
• The company reported publication on GLOPERBA dosing adjustments in a peer-reviewed journal [N6].
• Scilex regained compliance with Nasdaq minimum closing bid price requirement as of April 30, 2025 [N7].